Today
Downgrade
Show Hide Related Items >> <<
01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 11/27/20 Sage Therapeutics trading resumes 11/27/20 Sage Therapeutics to resume trading at 8 am ET 05:08 Today BMO Capital Sage Therapeutics downgraded to Market Perform from Outperform at BMO Capital 01/19/21 Wedbush Sage Therapeutics price target raised to $98 from $83 at Wedbush 01/04/21 Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation 01/04/21 Guggenheim Sage Therapeutics upgraded to Buy from Neutral at Guggenheim 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) 08/10/20 Sage Therapeutics reports Q2 EPS ($2.63), consensus ($2.66) 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 11/27/20 Fly Intel: Wall Street's top stories for Friday 11/27/20 Fly Intel: Pre-market Movers
Downgrade
BMO Capital analyst Gary…
BMO Capital analyst Gary Nachman downgraded Sage Therapeutics to Market Perform from Outperform with a $95 price target.
Show Hide Related Items >> <<
01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 11/27/20 Sage Therapeutics trading resumes 11/27/20 Sage Therapeutics to resume trading at 8 am ET 01/19/21 Wedbush Sage Therapeutics price target raised to $98 from $83 at Wedbush 01/04/21 Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation 01/04/21 Guggenheim Sage Therapeutics upgraded to Buy from Neutral at Guggenheim 01/04/21 RBC Capital Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) 08/10/20 Sage Therapeutics reports Q2 EPS ($2.63), consensus ($2.66) 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 11/27/20 Fly Intel: Wall Street's top stories for Friday 11/27/20 Fly Intel: Pre-market Movers
Tuesday
Conference/Events
Catalyst's…
Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link
Show Hide Related Items >> <<
CBIO Catalyst Biosciences 12/07/20 Catalyst Biosciences presents Crimson 1 Phase 3 study design 12/02/20 Catalyst Biosciences receives FDA fast track designation for MarzAA 10/14/20 Catalyst Biosciences receives patent for anti-complement Factor 3 portfolio 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/14/21 Truist Truist says FDA wouldn't be discussing label if not going to approve aducanumab 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist CBIO Catalyst Biosciences 12/02/20 Raymond James Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James 05/21/20 Raymond James Catalyst Biosciences initiated with an Outperform at Raymond James CBIO Catalyst Biosciences 11/05/20 Catalyst Biosciences reports Q3 EPS (73c), consenus (81c) 08/06/20 Catalyst Biosciences reports Q2 EPS (96c), consenus (86c) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open
Recommendations
Wedbush analyst Laura…
Wedbush analyst Laura Chico raised the firm's price target on Sage Therapeutics to $98 from $83 and keeps an Outperform rating on the shares. Following management's latest 2021 strategic outlook, and ahead of potential Phase 2 KINETIC data for SAGE-324 in essential tremor, the analyst is formally assigning credit for the program in her model. In terms of what to expect from the upcoming readout, Chico would look for similar magnitudes of reduction in tremor via accelerometry. On safety, the analyst looks for greater clarity around sedative effects, but would look to later studies to find strategies to offset somnolence.
Show Hide Related Items >> <<
01/07/21 Sage Therapeutics plans to advance SAGE-319, SAGE-421 to preclinical studies 12/16/20 Sage Therapeutics names Barry Greene as CEO 11/27/20 Sage Therapeutics trading resumes 11/27/20 Sage Therapeutics to resume trading at 8 am ET 01/04/21 Sage Therapeutics downgraded to Sector Perform at RBC Capital on valuation 01/04/21 Guggenheim Sage Therapeutics upgraded to Buy from Neutral at Guggenheim 01/04/21 RBC Capital Sage Therapeutics downgraded to Sector Perform from Outperform at RBC Capital 12/04/20 Fly Intel: Top five analyst upgrades 11/05/20 Sage Therapeutics reports Q3 EPS ($2.03), consensus ($2.39) 08/10/20 Sage Therapeutics reports Q2 EPS ($2.63), consensus ($2.66) 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 11/27/20 Fly Intel: Wall Street's top stories for Friday 11/27/20 Fly Intel: Pre-market Movers
Conference/Events
Catalyst's…
Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link
Show Hide Related Items >> <<
CBIO Catalyst Biosciences 12/07/20 Catalyst Biosciences presents Crimson 1 Phase 3 study design 12/02/20 Catalyst Biosciences receives FDA fast track designation for MarzAA 10/14/20 Catalyst Biosciences receives patent for anti-complement Factor 3 portfolio 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/14/21 Truist Truist says FDA wouldn't be discussing label if not going to approve aducanumab 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist CBIO Catalyst Biosciences 12/02/20 Raymond James Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James 05/21/20 Raymond James Catalyst Biosciences initiated with an Outperform at Raymond James CBIO Catalyst Biosciences 11/05/20 Catalyst Biosciences reports Q3 EPS (73c), consenus (81c) 08/06/20 Catalyst Biosciences reports Q2 EPS (96c), consenus (86c) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open
Over a week ago
Conference/Events
Catalyst's…
Catalyst's management team provides an overview of the Company's recently introduced complement programs, as well as ongoing developments with CB 2782, a novel engineered C3 degrader partnered with Biogen, on a conference call to be held on January 19 at 1pm hosted by LifeSci Capital. Webcast Link
Show Hide Related Items >> <<
CBIO Catalyst Biosciences 12/07/20 Catalyst Biosciences presents Crimson 1 Phase 3 study design 12/02/20 Catalyst Biosciences receives FDA fast track designation for MarzAA 10/14/20 Catalyst Biosciences receives patent for anti-complement Factor 3 portfolio 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/14/21 Truist Truist says FDA wouldn't be discussing label if not going to approve aducanumab 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist CBIO Catalyst Biosciences 12/02/20 Raymond James Catalyst Biosciences gets Fast Track for MarzAA, says Raymond James 05/21/20 Raymond James Catalyst Biosciences initiated with an Outperform at Raymond James CBIO Catalyst Biosciences 11/05/20 Catalyst Biosciences reports Q3 EPS (73c), consenus (81c) 08/06/20 Catalyst Biosciences reports Q2 EPS (96c), consenus (86c) 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open
Conference/Events
Webinar focuses on…
Webinar focuses on Biogen's data from trials investigating the efficacy and safety of aducanumab, an investigational treatment for early Alzheimer's disease, on January 14 at 2 pm. Webcast Link
Show Hide Related Items >> <<
$278.62 / +11.92 (+4.47%)
01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products $278.62 / +11.92 (+4.47%)
01/14/21 Truist Truist says FDA wouldn't be discussing label if not going to approve aducanumab 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist $278.62 / +11.92 (+4.47%)
10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open $278.62 / +11.92 (+4.47%)
11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says $278.62 / +11.92 (+4.47%)
01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street $278.62 / +11.92 (+4.47%)
09/15/20 Alexion strength attributed to takeover speculation $278.62 / +11.92 (+4.47%)
01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th
Recommendations
Following the aducanumab…
Following the aducanumab presentation at the Alzheimer's Disease International meeting, Truist analyst Robyn Karnauskas said one of her main takeaways was that the SVP and Head of the neurodegeneration development unit at Biogen, Samantha Budd Haeberlein, noted that how much imaging will be appropriate for monitoring treatment with the drug if approved is a conversation the company is having with regulators. If regulators "were not going to approve adu they likely would not be discussing label" with Biogen, argues Karnauskas, who keeps a Buy rating and $443 price target on Biogen shares.
Show Hide Related Items >> <<
01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 09/15/20 Alexion strength attributed to takeover speculation 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th
Conference/Events
Webinar focuses on…
Webinar focuses on Biogen's data from trials investigating the efficacy and safety of aducanumab, an investigational treatment for early Alzheimer's disease, on January 14 at 2 pm. Webcast Link
Show Hide Related Items >> <<
01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 09/15/20 Alexion strength attributed to takeover speculation 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th
Conference/Events
Conference call to review…
Conference call to review the Aducanumab data will be held on January 14 at 9 am. Webcast Link
Show Hide Related Items >> <<
01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 11/07/20 Biogen Alzheimer's drug closer to approval, still not a buy, Barron's says 11/07/20 FDA may find it 'extremely' hard to approve Biogen drug after panel, STAT says 09/28/20 Biogen loses appeal in fight seeking royalties from Merck KGaA, Bloomberg says 09/28/20 Biogen loses appeal ruling on MS drug Rebif, Bloomberg says 01/11/21 Fly Intel: Wall Street's top stories for Monday 01/11/21 Fly Intel: Wall Street's top stories at midday 01/11/21 Eli Lilly and Alzheimer's research peers jump after study meets endpoint 12/04/20 Delta, United, Boeing downgrades among today's top calls on Wall Street 09/15/20 Alexion strength attributed to takeover speculation 01/08/21 Biogen put volume heavy and directionally bearish 11/11/20 Early notable gainers among liquid option names on November 11th 11/05/20 Unusually active option classes on open November 5th 09/28/20 Early notable gainers among liquid option names on September 28th